StockData

Context Therapeutics vs TuHURA Biosciences

CNTX and HURA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CNTX and HURA compare

TuHURA Biosciences is the larger company, worth 5.7 times as much as Context Therapeutics ($89.2M against $15.7M).

Context Therapeutics scores higher on the StockData Score (6 against 0 for TuHURA Biosciences), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCNTXHURA
Size and price
Market cap$15.7M$89.2M
Share price$0.171$1.40
Change, 1 year−85.3%−31.7%
Change, 5 years−96.6%−99.9%
Beta (5Y)0.091.98
Employees1522
StockData Score
Total score6 (better)0
Valuation score1 (better)0
Growth score00
Performance score00
Health score5 (better)0
Dividend score00
Valuation
P/B0.4× (better)4.8×
FCF yield−217%−33.5% (better)
Profitability
Return on equity−76.1% (better)−161%
Financial health
Debt / equity0.00–
Current ratio5.81 (better)0.18
Altman Z-score−5.99−3.21 (better)
Piotroski F-score3 (better)2
Dividends and buybacks
Buyback yield−0.10% (better)−22.6%
Shareholder yield−0.10% (better)−22.6%
Ownership
Held by institutions68.4%14.1%
Held by insiders1.9%4.9%
Short interest, % of float5.2%10.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.